Owing to the potential danger of spreading COVID – 19 and as directed by AMFI, to ensure safety of our investors, partners and employees, all our AMC branches are temporarily closed until further notice. However, we will be working from home and will be at your service. We urge our investors and partners to make use of various other digital modes available for making transactions. For any queries, please write to us at crmf@canararobeco.com. You may also call us at 1800-209-2726 during working hours.
We will be continuously monitoring the situation and shall update the status once the normal operations are resumed. We would like to reiterate that serving you well is our top priority and shall attempt to make your investment journey a memorable one with Canara Robeco.
With effect from December 9, 2013, U.S. Persons and Residents of Canada are not permitted to invest in any of the Schemes of Canara Robeco Mutual Fund. Read the issuednotice cum addendum in this reference.
This product is suitable for investors who are seeking *
Long term capital growth.
Investment in equity and equity related instruments by following value investing strategy.
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
Comparative performance of Canara Robeco Value Fund - Reg - Growth
| Canara Robeco Value Fund - Reg - Growth | Scheme Benchmark (BSE 500 TRI) | Additional Benchmark (BSE Sensex TRI) | |
|---|---|---|---|
| CAGR since Inception | 20.48 % | 15.26 % | 11.65 % |
| 1 Year | 28.89 % | 27.01 % | 20.59 % |
| 3 Year | 22.50 % | 16.85 % | 13.28 % |
| 5 Year | NA | NA | NA |
| Current Value of 10,000 invested at inception | ` 18290.00 | ` 15847.00 | ` 14294.00 |
Equities95.09%
Debt Instruments0.00%
Government Bonds0.00%
Money Market0.00%
Others4.91%
Asset Allocation as on
Portfolio Turnover Ratio0.33
Regular Plan2.16 %
Direct Plan0.64 %
Note – Scheme may or may not have any future position in the above Sectors(s) / Stock(s) / Issuer(s)
NAV As on 20-Dec-2024
60.25-0.98 (-1.60%)CAGRSince Inception
13.34%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investing predominantly in equities and equity related instruments of large cap companies
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
106.88-1.91 (-1.76%)CAGRSince Inception
16.78%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investing in equity and equity related securities of companies following the Consumption and Financial Theme
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
171.26-2.89 (-1.66%)CAGRSince Inception
19.57%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investment in equity and equity related securities with a statutory lock in of 3 years and tax benefit
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
253.1-5.48 (-2.12%)CAGRSince Inception
17.73%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investing predominantly in equities and equity related instruments of both large cap and mid cap companies
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
325.3-5.35 (-1.62%)CAGRSince Inception
17.78%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investment in equity and equity related instruments across large cap, mid cap, small cap stocks
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
19.3-0.26 (-1.33%)CAGRSince Inception
20.06%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investment in equity and equity related securities across market capitalisation in maximum 30 stocks.
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
157.85-3.35 (-2.08%)CAGRSince Inception
15.57%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investing in equities and equity related instruments of companies following the Infrastructure Theme
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
12.33-0.27 (-2.14%)CAGRSince Inception
NAVery High Risk
This product is suitable for investors who are seeking *
Long term capital appreciation
Investments in equity and equity related instruments of companies engaged in the manufacturing theme
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
16.55-0.41 (-2.42%)CAGRSince Inception
27.83%Very High Risk
This product is suitable for investors who are seeking *
Long term capital appreciation
Investments predominantly in equity and equity related instruments of mid cap companies.
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
14.17-0.27 (-1.87%)CAGRSince Inception
28.27%Very High Risk
This product is suitable for investors who are seeking *
Long term capital appreciation
Investment in equity and equity related instruments across large cap, mid cap, small cap stocks
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
40.37-0.88 (-2.13%)CAGRSince Inception
26.94%Very High Risk
This product is suitable for investors who are seeking *
Capital appreciation over long term
Investing predominantly in equities and equity related instruments of small cap companies
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
